ClinicalTrials.gg
Active, not recruitingNCT07193017Updated Nov 18, 2026

The Effect of BIPAP on Diaphragmatic Function

An observational study in BIPAP Biphasic Intermittent Positive Airway Pressure, Diaphragm Issues and Ultrasound Diagnostics, sponsored by Istanbul Demiroglu Bilim University. Active, not recruiting at 1 site in Turkey (Türkiye). Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Istanbul Demiroglu Bilim University · Observational

How we know

Updated Nov 18, 2026Now Active, not recruitingPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey — 58 open to participants now, 68 under way, 7 of them phase 3. Pulmonary Disease, Chronic Obstructive · Turkey.

Planned enrollment
55th of 60
30 · median 77
Started
2025
with 26 others
Observational
60 of 248
19 open now
Primary completion
2027-03
later than 57 of 67 live
Registered
218th of 248
by date

Among the 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey, this one is the 55th largest by planned enrollment of the 60 observational ones that give a count, is one of 27 that started in 2025, is one of 60 observational ones, reaches primary completion later than 57 of the 67 other live ones, and was the 218th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

58 of the 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 248 studies in Pulmonary Disease, Chronic Obstructive with a site in Turkey, or all of them as a file.
02

Study summary

This research is designed to evaluate how long-term treatment with Bilevel Positive Airway Pressure (BiPAP) influences diaphragm function in patients with Chronic Obstructive Pulmonary Disease (COPD) who suffer from chronic hypercapnic respiratory failure. The diaphragm is the primary muscle of breathing, and its dysfunction is linked to unfavorable clinical outcomes such as higher mortality rates and frequent hospitalizations. In this prospective cohort study, COPD patients starting BiPAP therapy based on clinical indication will be monitored through repeated ultrasound assessments of diaphragm structure and function together with pulmonary function testing, respiratory muscle strength evaluation, dyspnea. The main outcome of interest is the change in diaphragm thickness in inspiration, thickness in expiration, diaphragm thickening fraction (DTF), diaphragm maximum contraction velocity and maximum relaxation velocity across a 6 weeks as a early time and 12 months for long time follow-up period. Secondary measures include hospital admissions, and one-year survival. The study is expected to generate valuable evidence about the link between non-invasive ventilation and diaphragm function, which may contribute to optimizing treatment strategies for COPD patients with advanced respiratory failure.

Read the detailed description

Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition frequently complicated by chronic hypercapnic respiratory failure. In this population, long-term non-invasive ventilation with bilevel positive airway pressure (BiPAP) is widely prescribed to improve gas exchange, relieve symptoms, and reduce the risk of hospitalizations. However, its effects on diaphragm function, the main respiratory muscle, remain poorly understood. Diaphragm dysfunction in COPD has been associated with adverse outcomes including increased mortality, prolonged hospital stay, and higher readmission rates.

This prospective cohort study aims to evaluate the longitudinal impact of BiPAP treatment on diaphragm structure and function in patients with COPD and chronic hypercapnic respiratory failure. Eligible participants will be patients who are prescribed BiPAP therapy according to standard clinical indications. Diaphragm function will be assessed repeatedly using ultrasonography, which provides non-invasive and reliable measurements of diaphragm thickness at end-inspiration and end-expiration, thickening fraction (DTF), maximum contraction velocity, and maximum relaxation velocity. These measurements will be complemented by pulmonary function tests, respiratory muscle strength evaluations, and dyspnea assessment.

The primary outcome is the change in diaphragm ultrasound parameters (inspiratory thickness, expiratory thickness, thickening fraction, contraction velocity, and relaxation velocity) over the course of treatment. Early follow-up will occur at 6 weeks to assess short-term effects, while long-term follow-up at 12 months will provide insight into sustained adaptations to BiPAP therapy. Secondary outcomes include the frequency of hospital admissions and overall one-year survival.

By integrating functional, structural, and clinical outcomes, the study is expected to provide novel evidence on the role of non-invasive ventilation in modifying diaphragm performance. Findings may contribute to refining treatment strategies and optimizing long-term management of COPD patients with advanced respiratory failure.

03

Conditions studied

  • BIPAP Biphasic Intermittent Positive Airway Pressure
  • Diaphragm Issues
  • Ultrasound Diagnostics
  • COPD (Chronic Obstructive Pulmonary Disease)

Keywords

  • bıpap, diaphragm function, diaphragm ultrasound, copy
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

COPD patient prescribed BIPAP

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being between 40-80 years of age,
  • Having a diagnosis of stable for at least 1 year,
  • Being in a stable phase (no acute exacerbation within the last 4 weeks),
  • Meeting the GOLD 2025 A-B-E classification according to symptoms and exacerbation history,
  • Having been initiated on BiPAP therapy with a clinical indication,
  • Being willing to participate in the study and providing .

Exclusion criteria

Exclusion Criteria:

  • Pregnancy,
  • Diaphragmatic paralysis,
  • Neuromuscular and neurological diseases,
  • Decompensated heart failure,
  • Chest deformity,
  • Acute exacerbation within the last month,
  • Pneumothorax,
  • greater than 35 kg/m²,
  • Long-term use,
  • Chemotherapy,
  • Active ,
  • Inability to cooperate,
  • Thoracoabdominal surgery within the last 3 months.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • copd patients

    Patients diagnosed with chronic obstructive pulmonary disease (COPD) who have been prescribed BiPAP therapy by a physician. Participants will undergo diaphragmatic function evaluations with ultrasound at baseline, after 6 weeks of BiPAP usage, and after one year.

    Device: BIPAP

Interventions

  • DeviceBIPAP

    After BIPAP Prescribed By A Physician, Diaphragmatic Functions Will Be Evaluated With Ultrasound In The Early And Late Periods

06

What researchers measure

Primary outcomes

  1. One-Year Survival

    Survival status (alive or deceased) will be assessed at 12 months after initiation of BiPAP therapy. This will be recorded as a binary outcome.

    Time frame: at baseline and after 12 months

  2. Number of Hospital Admissions within 12 Months

    The number of hospital admissions due to respiratory or other causes will be recorded during the 12-month follow-up period. A higher number indicates greater healthcare utilization.

    Time frame: at baseline and after 12 months

  3. Maximum Inspiratory Pressure (MIP)

    Respiratory muscle strength will be assessed using maximum inspiratory pressure (MIP), measured with a portable mouth pressure device according to standard guidelines. Higher values indicate better inspiratory muscle function.

    Time frame: Baseline, after 6 weeks of BiPAP usage, and after one year

  4. Maximum Expiratory Pressure (MEP)

    Respiratory muscle strength will be assessed using maximum expiratory pressure (MEP), measured with a portable mouth pressure device according to standard guidelines. Higher values indicate better expiratory muscle function.

    Time frame: At baseline, after 6 weeks of BiPAP usage, and after one year.

  5. Forced Vital Capacity (FVC)

    Forced Vital Capacity (FVC) will be measured using a portable spirometer calibrated according to American Thoracic Society (ATS) and European Respiratory Society (ERS) standards. The best result from at least three attempts will be recorded.

    Time frame: Baseline, after 6 weeks of BiPAP usage, and after one year.

  6. Forced Expiratory Volume in 1 Second (FEV₁)

    Forced Expiratory Volume in 1 second (FEV₁) will be measured using a portable spirometer calibrated according to ATS/ERS standards. The best result from at least three attempts will be recorded.

    Time frame: Baseline, after 6 weeks of BiPAP usage, and after one year.

  7. FEV₁/FVC Ratio

    FEV₁/FVC ratio will be calculated from spirometry results. The best result from at least three attempts will be recorded.

    Time frame: Baseline, after 6 weeks of BiPAP usage, and after one year.

  8. Cough Strength (Peak Cough Flow, PCF)

    Peak Cough Flow (PCF) will be measured using a peak flow meter.

    Time frame: Baseline, after 6 weeks of BiPAP usage, and after one year.

  9. Diaphragm Thickness (B-mode Ultrasound)

    Diaphragm thickness will be measured in two-dimensional B-mode ultrasound from the right intercostal area (mid-axillary level), the right subcostal area (anterior axillary level and mid-clavicular level) with a superficial probe during deep inspiration and deep expiration.

    Time frame: Baseline, after 6 weeks of BiPAP usage, and after one year.

  10. Diaphragm Excursion (M-mode Ultrasound)

    Diaphragm mobility during normal inspiration and deep inspiration will be assessed using M-mode ultrasonography from the right subcostal area at the mid-axillary level.

    Time frame: Baseline, after 6 weeks of BiPAP usage, and after one year.

  11. Diaphragmatic Tissue Velocity (Tissue Doppler Imaging)

    Diaphragmatic tissue waveform and movement velocities during inspiration and expiration will be assessed using tissue Doppler ultrasonography. Maximum contraction and relaxation rates of the diaphragm will be recorded during 10 normal breaths.

    Time frame: Baseline, after 6 weeks of BiPAP usage, and after one year.

Secondary outcomes

  1. COPD Assessment Test (CAT) Score:

    CAT will be used to assess health status impairment in patients with respiratory symptoms. Higher scores indicate greater symptom burden.

    Time frame: at baseline and after 6 weeks of BIPAP usage and after one year

  2. Dyspnea (mMRC Scale)

    Dyspnea severity will be evaluated using the modified Medical Research Council (mMRC) dyspnea scale, ranging from 0 (no dyspnea) to 4 (severe dyspnea).

    Time frame: at baseline and after 6 weeks of BIPAP usage and after one year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Mar 2027, 17 months after the start.

Of 469 non-industry observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 62. This study's planned 17 months is below that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Mar 2027, on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 25, 2025
StartActual
Oct 15, 2025
Primary completionEst.
Mar 15, 2027was Oct 2026
CompletionEst.
Jun 15, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Nov 18, 2026
Primary completion
Oct 15, 2026→Mar 15, 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Not yet recruiting→Active, not recruiting
    Primary completion Oct 15, 2026→Mar 15, 2027
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07193017
Lead sponsor
Istanbul Demiroglu Bilim University
Collaborators
Istanbul Sureyyapasa Chest Diseases and Chest Surgery Training and Research Hospital
Responsible party
Reyhan Kaygusuz (Assistant Professor, Istanbul Demiroglu Bilim University) — Principal investigator
First posted
Sep 25, 2025
Start date
Oct 15, 2025
Primary completion
Mar 15, 2027 (estimated)
Completion
Jun 15, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Reyhan Kaygusuz Benli, Asst Prof
principal investigator · Demiroglu Bilim University, Dept. of Physiotherapy and Rehabilitation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion